Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.270
+0.150 (3.64%)
At close: Apr 9, 2026, 4:00 PM EDT
4.333
+0.063 (1.48%)
After-hours: Apr 9, 2026, 4:02 PM EDT
Precigen Revenue
In the year 2025, Precigen had annual revenue of $9.68M with 146.73% growth. Precigen had revenue of $4.57M in the quarter ending December 31, 2025, with 283.61% growth.
Revenue (ttm)
$9.68M
Revenue Growth
+146.73%
P/S Ratio
147.29
Revenue / Employee
$60,525
Employees
160
Market Cap
1.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | 5.76M | 146.73% |
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Iovance Biotherapeutics | 263.50M |
| Viridian Therapeutics | 70.85M |
| Vir Biotechnology | 68.56M |
| Immatics | 56.67M |
| Nanobiotix | 38.27M |
| Generate Biomedicines | 31.89M |
PGEN News
- 2 days ago - Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - Accesswire
- 10 days ago - Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - PRNewsWire
- 14 days ago - These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
- 15 days ago - Precigen Reports Full Year 2025 Financial Results and Business Updates - PRNewsWire
- 4 weeks ago - Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 - PRNewsWire
- 2 months ago - New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 3 months ago - Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire